GOSS
Gossamer Bio, Inc.
$0.17
+0.01 (+2.98%)
At close · Jul 2
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$40.65M
Shares
234,696,281
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.17
Open$0.17
Day$0.16–0.18
52W$0.14–3.87
Avg vol 30d16.3M
Short int56.2M · 24.0% float · 3.4d
Short vol50%
Last earningsMay 18, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−89% below
−
Price vs 50-day avg
−29% below
◦
RSI (14)
41 · neutral
+
MACD trend
positive
−
52-week position
1% · near low
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $0 › 200d $2 — 200d above 50d
−
Institutional flow
-5% holders QoQ · +48 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
23.95% of float · ▼ -10.5% MoM · 3.4 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
191 holders — mid 3-yr range
Fundamentals
Weak
−
Revenue growth
−58% Y/Y
−
EPS growth
−200% Y/Y
−
Free cash flow
$-171.3M
+
Balance sheet
net cash $9.3M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−89% below
Bearish
Price vs 50-day avg
−29% below
Bearish
RSI (14)
41 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
1% · near low
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-5% holders QoQ · +48 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
23.95% of float · ▼ -10.5% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
191 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 1%
52-wk high $4
vs 200-day avg -89%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GOSS
this stock
Gossamer Bio, Inc.
|
$40.65M | -94.4% | — | — | 24.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GOSS | +4.9% | -8.0% | -93.1% | +4.9% | -94.4% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +3.4% | -6.7% | -101.1% | +5.1% | -103.6% |
Key facts
CIK
1728117
CUSIP
38341P102
13F (30d)
6 filings
5 filers